Axsome Therapeutics, Inc.
AXSMNASDAQHealthcare● Active
$237.57
+$5.25(+2.26%)
Market Cap$12.2B
P/E Ratio—
52W High$239
52W Low$96.09
Axsome Therapeutics, Inc. (AXSM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AXSM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$1.26
Est. -$0.85 · -48.2%
Revenue
$0.19B
Est. $0.19B · -0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS
AXSM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$0.83 | — | — | — | $0.22B | — |
| ▼ Q2 FY2026 | May 4, 2026 | -$0.85 | -$1.26 | -48.2% | $0.19B | $0.19B | -0.8% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -$0.70 | -$0.71 | -1.4% | $0.19B | $0.19B | +0.7% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -$0.82 | -$0.94 | -14.6% | $0.17B | $0.19B | -10.6% |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$1.00 | -$0.92 | +8.0% | $0.15B | $0.14B | +7.2% |
| ▲ Q2 FY2025 | May 5, 2025 | -$1.26 | -$0.80 | +36.5% | $0.12B | $0.14B | -13.5% |
| ▲ Q1 FY2025 | Feb 18, 2025 | -$1.00 | -$0.96 | +4.0% | $0.12B | $0.12B | -0.6% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$1.38 | -$1.34 | +2.9% | $0.10B | $0.10B | +6.5% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$0.83
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
-$1.26
EPS Est.
-$0.85
EPS Surpr.
-48.2%
Revenue
$0.19B
Q1 FY2026
Feb 23, 2026Miss
EPS Actual
-$0.71
EPS Est.
-$0.70
EPS Surpr.
-1.4%
Revenue
$0.19B
Q4 FY2025
Nov 3, 2025Miss
EPS Actual
-$0.94
EPS Est.
-$0.82
EPS Surpr.
-14.6%
Revenue
$0.17B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
-$0.92
EPS Est.
-$1.00
EPS Surpr.
+8.0%
Revenue
$0.15B
Q2 FY2025
May 5, 2025Beat
EPS Actual
-$0.80
EPS Est.
-$1.26
EPS Surpr.
+36.5%
Revenue
$0.12B
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
-$0.96
EPS Est.
-$1.00
EPS Surpr.
+4.0%
Revenue
$0.12B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$1.34
EPS Est.
-$1.38
EPS Surpr.
+2.9%
Revenue
$0.10B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $3.79 | $4.53 | $5.31 | 5 |
| Q3 FY2028 | $3.07 | $3.67 | $4.30 | 5 |
| Q2 FY2028 | $2.62 | $3.13 | $3.67 | 6 |
| Q1 FY2028 | $2.02 | $2.42 | $2.84 | 3 |
| Q4 FY2027 | $1.39 | $1.66 | $1.95 | 2 |
| Q3 FY2027 | $0.95 | $1.14 | $1.33 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.6B | $0.7B | $0.8B | 8 |
| Q3 FY2028 | $0.5B | $0.6B | $0.6B | 6 |
| Q2 FY2028 | $0.4B | $0.5B | $0.5B | 5 |
| Q1 FY2028 | $0.3B | $0.4B | $0.4B | 5 |
| Q4 FY2027 | $0.4B | $0.5B | $0.5B | 6 |
| Q3 FY2027 | $0.3B | $0.4B | $0.5B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -48.2% | $206.53 | $223.70 | +8.31% |
| ▼ Q1 FY2026 | Feb 23, 2026 | -1.4% | $183.72 | $174.76 | -4.88% |
| ▼ Q4 FY2025 | Nov 3, 2025 | -14.6% | $134.99 | $135.75 | +0.56% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +8.0% | $103.02 | $106.54 | +3.42% |
| ▲ Q2 FY2025 | May 5, 2025 | +36.5% | $112.21 | $116.49 | +3.81% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +4.0% | $131.15 | $128.09 | -2.33% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +2.9% | $90.98 | $99.49 | +9.35% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +4.6% | $84.42 | $83.21 | -1.43% |
Q2 FY2026+8.31%
Report Date
May 4, 2026
EPS Beat/Miss
-48.2%
Price Before
$206.53
Price After
$223.70
Q1 FY2026-4.88%
Report Date
Feb 23, 2026
EPS Beat/Miss
-1.4%
Price Before
$183.72
Price After
$174.76
Q4 FY2025+0.56%
Report Date
Nov 3, 2025
EPS Beat/Miss
-14.6%
Price Before
$134.99
Price After
$135.75
Q3 FY2025+3.42%
Report Date
Aug 4, 2025
EPS Beat/Miss
+8.0%
Price Before
$103.02
Price After
$106.54
Q2 FY2025+3.81%
Report Date
May 5, 2025
EPS Beat/Miss
+36.5%
Price Before
$112.21
Price After
$116.49
Q1 FY2025-2.33%
Report Date
Feb 18, 2025
EPS Beat/Miss
+4.0%
Price Before
$131.15
Price After
$128.09
Q4 FY2024+9.35%
Report Date
Nov 12, 2024
EPS Beat/Miss
+2.9%
Price Before
$90.98
Price After
$99.49
Q3 FY2024-1.43%
Report Date
Aug 5, 2024
EPS Beat/Miss
+4.6%
Price Before
$84.42
Price After
$83.21
Avg Beat Reaction+2.56%
Avg Miss Reaction+1.33%
Beat Rate5 / 8 quarters
Largest Move+9.35% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AXSM ends December
Axsome Therapeutics, Inc. (AXSM) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-1.26 — missing the analyst consensus of $-0.85 by -48.2%. The next AXSM earnings date is expected around September 1, 2026.
Each quarter, investors track AXSM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AXSM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AXSM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AXSM earnings · 5 questionsAxsome Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. AXSM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AXSM historically reports after market close (AMC).
AXSM earnings datewhen is AXSM earningsAXSM next earnings datewhen does AXSM report earningsAXSM earnings calendar
▸ Source: FMP · Axsome Therapeutics, Inc. SEC filings · US GAAP · Axsome Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026